What sample preparation should be chosen for targeted MS monoclonal antibody quantification in human serum?
What sample preparation should be chosen for targeted MS monoclonal antibody quantification in human serum?
复制标题
对人血清中的靶向 MS 单克隆抗体定量应选择什么样品制备？
DOI：
10.4155/bio-2018-0027
复制
发表时间：
2018
期刊：
影响因子：
1.8
通讯作者：
C. Hirtz
中科院分区：
文献类型：
--
作者：
J. Vialaret;S. Broutin;Célia Pugnier;Sophie Santelé;A. Jaffuel;A. Barnes;L. Tiers;L. Pelletier;S. Lehmann;A. Paci;C. Hirtz
目的
AIM
Monoclonal antibody-based treatment of cancer has been established as one of the most successful therapeutic strategies.
MATERIALS & METHODS
In this work, we developed a workflow based on an automated protein-A capture and LC-MS/MS analysis to quantify bevacizumab on patient serum during treatment. This analytical approach was fully validated and compared with a commercially available Monoclonal antibody-based treatment preparation (nanosurface and molecular-orientation limited kit).
RESULTS
The analytical comparison of the two preparative workflows based on protein-A capture gave similar results with a better lower limit of quantification for the nanosurface and molecular-orientation limited kit (0.26986 vs 1.9565 μg/ml).
CONCLUSION
LC-MS/MS has clear advantages compared with ELISA when considering method development time, multiplexing capacities and absolute quantification with internal standardization.